The Journal focuses on ‘in vitro’, in vivo, cytochrome P450, Caco-2, and hepatocytes. In vitro studies are performed with microorganisms, cells, or biological molecules outside their normal biological context. Studies that are in vivo are those in which the effects of various biological entities are tested on whole, living organisms or cells, usually animals, including humans, and plants, as opposed to a tissue extract or dead organism. Cytochromes P450 (CYPs) are a superfamily of enzymes containing heme as a cofactor that function as monooxygenases. The Caco-2 cell line is a continuous line of heterogeneous human epithelial colorectal adenocarcinoma cells, developed by the Sloan-Kettering Institute for Cancer Research. A hepatocyte is a cell of the main parenchymal tissue of the liver. Hepatocytes make up 55-65% of the liver's mass. These cells are involved in: Protein synthesis, Protein storage.

The application of rapid methods currently used for screening discovery drug candidates for metabolism and pharmacokinetic characteristics is discussed. General considerations are given for screening in this context, including the criteria for good screens, the use of counter screens, the proper sequencing of screens, ambiguity in the interpretation of results, strategies for false positives and negatives, and the special difficulties encountered in drug metabolism and pharmacokinetic screening. Detailed descriptions of the present status of screening are provided for absorption potential, blood-brain barrier penetration, inhibition and induction of cytochrome P450, pharmacokinetics, biotransformation, and computer modeling. Although none of the systems currently employed for drug metabolism and pharmacokinetic screening can be considered truly high-throughput, several of them are rapid enough to be a practical part of the screening paradigm for modern, fast-moving discovery programs.

The Journal uses Editorial Manager System for a qualitative and prompt review process. Review processing is performed by the editorial board members of Journal of Pharmaceutical Sciences & Emerging Drugs or relevant experts from other universities or institutes. Minimum two independent reviewer’s approval followed by editor approval is required for the acceptance of any citable manuscript. Authors may submit manuscripts online / through mail id: pharmasci@scitecjournals.com and track their progress through the online tracking system, hopefully to publication.

Submit manuscripts as an e-mail attachment to the Editorial Office at editor.jpsed@peerjournal.org
A Manuscript number will be emailed to the corresponding author within 72 hours.

Thanks and Best Regards,
Editorial Manager
Journal of Pharmaceutical Sciences & Emerging Drugs
Email: editor.jpsed@peerjournal.org